Acumen Pharmaceuticals Inc (ABOS : NASDAQ)
Common Stock
$2.61
USD
+0.00 (%)
Last updated: 2026-09-17
Get ABOS alerts:
ABOS
Acumen Pharmaceuticals Inc
WealthAwesomePerformance
1 Day
-9.69%
1 Week
-8.42%
1 Month
-1.88%
YTD
+16.00%
Key Statistics
Market Cap
$188.75M
52W High
$3.60
52W Low
$1.22
P/E Ratio
-
50 Day MA
$2.62
200 Day MA
$2.48
Beta
0.38
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/17/2026 | $2.69 | $2.76 | $2.54 | $2.57 | $2.57 | 485,012 |
| 9/16/2026 | $2.92 | $2.95 | $2.59 | $2.61 | $2.61 | 368,850 |
| 9/15/2026 | $2.77 | $2.90 | $2.69 | $2.89 | $2.89 | 359,312 |
| 9/14/2026 | $2.91 | $3.02 | $2.78 | $2.79 | $2.79 | 394,216 |
| 9/11/2026 | $2.93 | $2.98 | $2.84 | $2.92 | $2.92 | 318,276 |
| 9/10/2026 | $2.79 | $2.90 | $2.73 | $2.86 | $2.86 | 467,800 |
| 9/9/2026 | $3.14 | $3.16 | $2.84 | $2.85 | $2.85 | 369,200 |
| 9/8/2026 | $3.14 | $3.29 | $3.08 | $3.16 | $3.16 | 358,100 |
| 9/4/2026 | $3.07 | $3.23 | $3.03 | $3.18 | $3.18 | 315,400 |
| 9/3/2026 | $3.13 | $3.17 | $3.05 | $3.09 | $3.09 | 452,300 |
Analyst Price Targets
Based on 5 analysts covering ABOS · as of Sep 17, 2026
Wall Street analysts forecast ABOS stock price to rise 183.5% over the next 12 months.
Consensus
Strong Buy5.00 / 5.00
Avg. Target
US$7.40
+183.5% Upside
Current Price
US$2.61
Last close
Analyst Breakdown (5 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ABOS's historical volatility
30-Day Vol
73.5%
Annualized
90-Day Vol
76.5%
Annualized
Trend (90d)
+27.0%
Annualized drift
90d Mean
US$2.83
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$2.65 | US$2.06 – US$3.42 |
| 60 trading days | US$2.74 | US$1.92 – US$3.92 |
| 90 trading days | US$2.83 | US$1.82 – US$4.39 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Financials
- Revenue (TTM)
- $329,000
- EBITDA
- $-105.37M
- Profit Margin
- 0.00%
- ROE (TTM)
- -120.51%
- EPS (Diluted)
- -1.48
- Book Value
- 0.79
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About ABOS.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |